Benzodiazepine Sedative-Hypnotic | Film-coated tablet | Controlled medicine
Composition: Each film-coated tablet contains Temazepam 15 mg; excipients q.s. (subject to approved label).
Usage: Short-term management of insomnia under medical supervision.
Therapeutic category: Benzodiazepine / Sedative-Hypnotic.
SKU: Temazepam Tablets 15 mg
Categories: Contract Manufacturer · Manufacturing Pharmaceutical Company India · Pharmaceutical Exporter India · Pharmaceutical Formulations India · Formulations Exporter India · Tablets Manufacturer · WHO GMP Certified Formulations
Temazepam Tablets is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Temazepam is a benzodiazepine hypnotic prescribed for short-term management of insomnia. The supplied composition identifies a 15 mg film-coated tablet. Healthy Life Pharma Pvt. Ltd. is named as manufacturer and Healthy Inc as exporter in the supplied description; manufacturing authorization, WHO-GMP certification, controlled-substance permissions and export eligibility require independent verification.
Content correction: Temazepam 15 mg, temazepam and erectile dysfunction references in the source text relate to a different medicine and have been excluded.
| Product name | Temazepam Tablets |
|---|---|
| Confirmed strength | 15 mg |
| Composition | Temazepam 15 mg per film-coated tablet |
| Dosage form | Film-coated tablet |
| Therapeutic class | Benzodiazepine / Sedative-hypnotic |
| Use | Short-term treatment of insomnia |
| Regulatory status | Controlled psychotropic medicine; licensing and market authorization required |
| Other strengths | 7.5 mg / 22.5 mg / 30 mg mentioned in background copy, not confirmed by supplied composition |
| Pharmacopoeial standard | Not specified for confirmed composition; verify registered product standard |
| Packaging and shelf life | Confirm from approved product dossier and stability studies |
Production of a low-dose controlled psychotropic tablet requires validated content uniformity, appropriate containment, traceable material reconciliation, restricted access, secure inventory control and validated cleaning. Granulation, coating and packaging methods must be supported by the manufacturer’s approved master formula and validation records; no specific equipment or process is assumed here.
Release testing should follow the registered specification and applicable pharmacopoeial monograph, including identity, assay, uniformity of dosage units, dissolution, related substances and stability. Batch reconciliation, controlled-drug registers and secure chain-of-custody procedures are especially important. Numerical limits and bioequivalence claims should not be published without supporting documents.
Temazepam enhances the effect of GABA at the GABA-A receptor complex, producing sedative-hypnotic effects. Its principal use is the short-term treatment of insomnia when clinically appropriate. It is not a treatment for erectile dysfunction. Treatment duration and continued need should be reviewed by the prescribing clinician.
Temazepam is a controlled psychotropic substance. Any manufacture, distribution, import or export must comply with applicable Indian law, destination-country controlled-drug rules, import permits, export authorizations and product registration requirements. Buyers should request current facility licenses, approved specifications, COA and supporting regulatory documentation. CTD/ACTD dossiers, COPP, FSC and WHO-GMP certificates are subject to actual availability and verification; no unrestricted export availability is implied.
Q: What strength is confirmed?
A: Temazepam 15 mg film-coated tablets.
Q: Is Temazepam the same as Temazepam?
A: No. Temazepam is a sedative-hypnotic; temazepam is used for erectile dysfunction. The temazepam text in the supplied composition is an apparent copy-paste error.
Q: Is it a controlled medicine?
A: Yes. Supply requires compliance with applicable prescription and psychotropic-substance controls.
Dosage must be individualized by a licensed prescriber using the locally approved label, considering age, frailty, other sedatives and respiratory conditions. The supplied product strength is 15 mg; this does not establish an appropriate dose for every patient. Take only as directed at bedtime when adequate time for sleep is available. Do not increase the dose, share the medicine or discontinue abruptly after sustained use without medical advice.
Boxed/major warnings: Benzodiazepines carry risks of abuse, misuse, addiction, physical dependence and potentially life-threatening withdrawal. Concomitant opioids can cause profound sedation, respiratory depression, coma and death. Alcohol and other CNS depressants increase these risks. Adverse effects include next-day drowsiness, dizziness, impaired coordination, memory disturbance and falls. Use requires special caution in older adults, sleep apnea, respiratory disease, pregnancy and patients with substance-use risk. Avoid driving or hazardous tasks if impaired. Seek emergency care for slowed breathing or inability to awaken.
Store securely in the original package, protected from moisture and excessive heat, at the temperature specified on the approved label. Keep out of reach of children and unauthorized persons. Confirm shelf life and exact storage conditions from approved stability documentation.
For professional and B2B reference. Prescribing information, manufacturing claims, certification and market-specific approvals require verification.